Homeopathy: Curative, Concurrent and Supportive Cancer Treatment Potential
Journal Title: Journal of Integrative Oncology - Year 2017, Vol 6, Issue 3
Abstract
Background: Homeopathy is used by 12 to 24% of European cancer patients, representing 40.4% of patients at European integrative cancer centers. In 2011, a Swiss literature review on homeopathy led to homeopathic treatment coverage in the Swiss national health insurance program. Homeopathy for curative pediatric cancer treatment is limited to 7.4% in the Netherlands, but, 76.5% of German parents will use homeopathy as part of their children’s cancer treatment. The purpose of this paper is to determine what is needed for homeopathy to play a larger role in curative, concurrent, and supportive cancer treatment. Methods: PubMed searches in September 2016 and January 2017 were performed with search terms “adverse effects, breast cancer, cancer, cervical cancer, endometrial cancer, homeopathy, ovarian cancer, prevention, treatment”. Curative, concurrent, and supportive homeopathic cancer treatments material was taken from these searches. Findings: At least five homeopathic formulations are immunologic adjuvants, activating natural killer cell destruction of cancer and virally infected cells. Ultramolecular Carcinosin, Phytolacca decandra, Conium, Thuja and Klimaktoplan® are appropriate for in vivo breast cancer trials. Lycopodium clavatum 5C and 15C are ready for in vivo cervical cancer trials. Sulphur 30C, may be considered for non-small cell lung adenocarcinoma treatment trials. Conventional cancer treatment associated anxiety, asthenia, depression, dermatitis, folliculitis, hot flushes, insomnia, nausea and vomiting, and stomatitis, respond to numerous homeopathic treatments including hetero-isotherapy. Conclusion & Significance: In vitro studies and retrospective case series indicate that homeopathy could provide curative cancer treatment for an array of cancers: Breast, cervix, gallbladder, liver, lung, oral, pancreas, periampullary, skin, and stomach. Appropriately designed randomized controlled trials (RCT) based on reproducible homeopathic treatments and clinical protocols, with intent-to-treat analysis will have increased validity. If these RCT have positive outcomes homeopathy will secure a position in curative, concurrent, and supportive cancer treatment.
Authors and Affiliations
Oroma B Nwanodi
Keywords
Related Articles
- EP ID EP348592
- DOI 10.4172/2329-6771.1000194
- Views 55
- Downloads 0
Nurses’ Knowledge and Perceptions of Advance Care Planning, an Ethical Responsibility
Discussions around advance care planning (ACP) do not mean making decisions about what to do at the end of life, but how to cope with disease and treatment. Studies suggest that HPs and patients are ambivalent when talki...
Second Primary Neoplasms: A Clinico-Pathological Analysis from a Sub Himalayan Cancer Centre in India
Background: There is a lifetime risk of developing another de novo malignancy in diagnosed cancer patients. Detection of new primary has increased due to advances in both diagnostic and treatment modalities. This article...
Statistical Tool in Integrated Oncology: Propensity Score Methods
Randomized controlled trials are viewed as the “gold” standard study designs to generate evidence on effectiveness of interventions. In some situations in which randomized experiments are not possible, or not ethical, or...
Rescue Therapy in Patient with Glioblastoma Multiforme Combining Chemotherapy, Hyperthermia, Phytotherapy
Glioblastoma multiforme is a pathology that is poorly treatable and tends towards recurrence. If surgically unresectable, at least without macroscopically visible residue, the prognosis is severe. Here is the case of a 6...
Approximation to the Patient with Tumor of Unknown Origin
The tumor of unknown origin constitutes 3-7% of the cancers studied and is one of the 10 most frequent cancer diagnoses. It is a malignant tumor whose first origin or identification is not done in the clinical history, i...